| (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; but-2-enedioic acid |
| (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)-1-pentanone O-(2-aminoethyl)oxime (Z)-2-butenedioate (1:1) |
| (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate |
| (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl)oxime maleate |
| (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl)-1-pent |
| (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate |
| (E)-5-Methoxy-1-[4-(triflurormethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate |
| (E)-Fluvoxamine Maleate |
| (Z)-2-butenedioic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| (Z)-but-2-enedioic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1) |
| 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime,(E)-, (Z)-2-butenedioate (1:1) |
| 2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine (2Z)-but-2-enedioate |
| 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1) |
| 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate |
| 54739-18-3 |
| 54739-18-3 (Parent) |
| 54739-20-7 |
| 5LGN83G74V |
| 61718-82-9 |
| 739F183 |
| A833394 |
| AB2000054 |
| AC-9541 |
| AKOS015961142 |
| AN-39241 |
| AS-11790 |
| AX8016087 |
| BG0368 |
| C15H21F3N2O2.C4H4O4 |
| C19H25F3N2O6 |
| CCG-213494 |
| CHEBI:5139 |
| CHEMBL1409 |
| CPD000466268 |
| CS-1839 |
| D00824 |
| Depromel |
| DTXSID3042558 |
| DU-23000 |
| DU23000 |
| Dumirox |
| EU-0100495 |
| F 2802 |
| F0858 |
| Faverin |
| Fevarin |
| Floxyfral |
| Fluvoxamine (maleate) |
| Fluvoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard |
| FLUVOXAMINE MALEATE |
| Fluvoxamine maleate (JP17/USAN) |
| Fluvoxamine maleate [USAN:USP] |
| Fluvoxamine maleate [USAN] |
| Fluvoxamine maleate, 1.0 mg/mL in methanol ((as free base)), certified reference material |
| Fluvoxamine maleate, British Pharmacopoeia (BP) Reference Standard |
| Fluvoxamine maleate, European Pharmacopoeia (EP) Reference Standard |
| Fluvoxamine Maleate, Pharmaceutical Secondary Standard; Certified Reference Material |
| Fluvoxamine maleate, solid |
| Fluvoxamine maleate, United States Pharmacopeia (USP) Reference Standard |
| HMS1571G11 |
| HMS2098G11 |
| HMS3261D11 |
| HMS3715G11 |
| HY-B0103A |
| J90043 |
| KB-209260 |
| LS-102000 |
| Luvox |
| Luvox (TN) |
| maleic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| Maveral |
| MK-264 |
| MLS000028469 |
| MLS000758271 |
| MLS001076285 |
| MLS001304717 |
| MLS001401391 |
| MolPort-003-666-870 |
| NCGC00093897-01 |
| NCGC00093897-02 |
| NCGC00261180-01 |
| NSC 309469 |
| NSC-309469 |
| NSC-759602 |
| NSC309469 |
| NSC759602 |
| Pharmakon1600-01505604 |
| s1336 |
| SAM001246977 |
| SCHEMBL35225 |
| SME 3110 |
| SME-3110 |
| SMR000058449 |
| SMR000466268 |
| SMR000653482 |
| SR-01000075613 |
| SR-01000075613-1 |
| SR-01000075613-3 |
| SR-01000075613-4 |
| SR-01000075613-6 |
| ST24035070 |
| TL8003932 |
| Tox21_500495 |
| UNII-5LGN83G74V |
